STOCK TITAN
  1. Home
  2. News
  3. BFRG

BULLFROG AI HLDGS INC - BFRG STOCK NEWS

Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.

Overview

BullFrog AI Holdings Inc. (NASDAQ: BFRG) is a clinical-phase biotechnology company that leverages artificial intelligence and machine learning to revolutionize drug development. The company integrates state-of-the-art data analytics with robust biological research to support the discovery and development of innovative pharmaceuticals and biologics. At its core, BullFrog AI is dedicated to overcoming challenges in drug discovery by streamlining the analysis of complex clinical and biological data.

Technology and Platform

The company is distinguished by its proprietary bfLEAP platform, an AI/ML-powered system engineered to manage scalability and flexibility issues that often hinder traditional research. This platform employs multi-dimensional analytics and causal AI to generate a comprehensive understanding of complex biological networks. By harnessing this technology, BullFrog AI enhances the precision of target discovery, identifies potential molecular subtypes, and extracts predictive biomarkers across various disease areas.

Business Model and Operations

BullFrog AI operates at the cutting edge of the biotechnology industry by channeling its innovative technology into targeted drug development programs. The company collaborates with leading research institutions to mine clinical data spanning early discovery to late-stage clinical trials. By integrating analytical techniques with deep scientific expertise, BullFrog AI aims to reduce failure rates in therapeutics development, thereby optimizing clinical trial execution and accelerating the path to market for life-saving treatments.

Research Collaborations and Scientific Initiatives

An essential element of BullFrog AI's strategy is its engagement in strategic collaborations. Its partnerships include joint research initiatives with renowned institutions, such as brain research centers and institutes specializing in genetic and molecular disorders. These collaborations have enabled BullFrog AI to push the boundaries in areas including liver diseases, obesity, neuropsychiatric disorders, and oncology. The company’s data-driven methodologies have not only refined patient selection for clinical trials but have also paved the way for the discovery of novel drug targets and potential biomarkers.

Market Position and Industry Impact

Within a competitive landscape where traditional drug development methodologies are often slow and cost-intensive, BullFrog AI’s approach presents a transformative shift. The integration of AI-driven analytics offers a unique differentiation by providing a more precise and efficient pathway from target discovery to clinical validation. This positioning aligns with a broader industry demand for technology-enabled solutions that can address the inherent challenges in clinical research and therapeutic development.

Key Capabilities and Value Proposition

  • Advanced Data Analytics: BullFrog AI uses causal AI and sophisticated machine learning algorithms to decipher complex biological data, thereby supporting critical decision-making in drug development.
  • Streamlined Drug Development: The proprietary bfLEAP platform is designed to reduce the development lifecycle by identifying potential therapeutic targets and biomarkers early in the research phase.
  • Strategic Collaborations: Engagement with top-tier research institutions reinforces the company's scientific credibility and offers avenues for joint research that deepen insights into disease mechanisms.
  • Innovative Research Applications: The company is involved in diverse therapeutic areas, including liver diseases, obesity, psychiatric conditions, and oncology, making it a relevant player across multiple healthcare segments.

Conclusion

BullFrog AI Holdings Inc. stands as a notable example of how artificial intelligence and machine learning are revolutionizing the biotechnology landscape. With its innovative bfLEAP platform and commitment to integrating data-driven insights with clinical research, the company is effectively addressing the complexities of modern drug development. This comprehensive approach fosters greater operational efficiency, robust scientific inquiry, and the potential for breakthrough discoveries in therapeutic treatments.

News

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

Rhea-AI Summary
BullFrog AI Holdings, Inc. announces a fireside chat with CEO Vin Singh and Dr. Daniel R. Weinberger to discuss groundbreaking collaboration with LIBD on psychiatric research using AI and machine learning. The partnership aims to provide new insights into brain disorders and potential treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
AI
-
News

WallachBeth Capital Announces Closing Of Bullfrog AI $5.7 Million Public Offering

Rhea-AI Summary
WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. has completed an underwritten public offering, raising approximately $5.7 million. The company offered 1,507,139 shares of common stock at a public offering price of $3.782 per share. Additionally, the underwriters have a 45-day option to purchase an additional 226,071 shares to cover over-allotments. The offering was managed by WallachBeth Capital, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.64%
Tags
offering AI
-
News

BullFrog AI Announces Closing of $5.7 Million Public Offering

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ:BFRG) has closed an underwritten public offering, raising approximately $5,700,000 in gross proceeds. The company intends to use the net proceeds for working capital and general corporate purposes. WallachBeth Capital, LLC acted as the sole book-running manager for the offering. The offering was made in accordance with a registration statement on Form S-1 (File No. 333-276740) filed with the SEC and became effective on January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.64%
Tags
offering AI
News

WallachBeth Capital Announces Bullfrog AI Pricing of $5.7 Million Public Offering

Rhea-AI Summary
WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. priced an underwritten public offering of 1,507,139 shares of common stock and accompanying warrants, with gross proceeds of approximately $5,700,000. The offering is expected to close on February 5, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
offering AI
-
News

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

Rhea-AI Summary
BullFrog AI Holdings, Inc. announced the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share, resulting in gross proceeds of approximately $5,700,000. The company also granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock and/or warrants to cover over-allotments. The net proceeds from the offering will be used for working capital and other general corporate purposes. The offering is expected to close on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
offering AI
-
News

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

Rhea-AI Summary
BullFrog AI Holdings, Inc. announces the appointment of two distinguished scientific advisors to its advisory board, Dr. Gwenn S. Smith and Dr. Jeremiah Wala. Dr. Smith brings expertise in brain imaging and neuropsychiatry, while Dr. Wala adds clinical insight and computational expertise to the company's scientific advisory board. Both advisors are expected to contribute to the company's mission of developing breakthrough therapies and improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
management AI
News

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

Rhea-AI Summary
BullFrog AI Holdings, Inc. announced early results from its collaboration with the Lieber Institute for Brain Development that could revolutionize the understanding and treatment of psychiatric disorders. The collaboration has successfully stratified brain expression data, offering unprecedented insights into psychiatric conditions. The proprietary data from LIBD included gene expression data from over 2,800 brain samples encompassing schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. Utilizing graph analytics, BullFrog AI and LIBD have, for the first time, clustered subjects based solely on their biological data, independent of their behavioral diagnoses. This innovative approach has yielded promising insights, highlighting distinct differences and similarities in biological pathways across various brain disorders. The market opportunity for new treatments in psychiatric disorders is vast and underserved, presenting a potential paradigm shift in treatment approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.83%
Tags
AI
-
News

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This patent further strengthens the intellectual property protection of BF-223 and related compounds, including positive results from a preclinical study demonstrating that BF-223 has anticancer activity in an animal model for glioblastoma. The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, addressing a key difficulty associated with the potential use of mebendazole for oncology indications. The company is looking forward to working with strategic partners to monetize this promising asset for the treatment of glioblastoma and other oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
AI
-
News

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announces CEO's participation in Webull LIVE! Healthcare Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences AI
News

BullFrog AI Issues Letter to Shareholders

Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has had an extraordinary year, marked by progress, innovation, and value-adding events. The company successfully completed an $8.4 million IPO listing on Nasdaq and secured an exclusive partnership with Lieber Institute for Brain Development. BullFrog AI has also made significant strides in drug development, including identifying drug targets for colorectal cancer and initiating pre-clinical studies for liver disease and obesity drug candidates. The company has strengthened its intellectual property, licensed improvements to its AI algorithms, and recorded its first earned revenue in the third quarter. BullFrog AI's CEO, Vin Singh, is optimistic about the future, emphasizing the company's focus on securing business and driving revenue through external contracts and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
AI

FAQ

What is the current stock price of BULLFROG AI HLDGS (BFRG)?

The current stock price of BULLFROG AI HLDGS (BFRG) is $1.41 as of April 3, 2025.

What is the market cap of BULLFROG AI HLDGS (BFRG)?

The market cap of BULLFROG AI HLDGS (BFRG) is approximately 13.3M.

What is BullFrog AI Holdings Inc.?

BullFrog AI Holdings Inc. is a technology-enabled drug development company that employs artificial intelligence and machine learning to enhance the discovery and development of pharmaceuticals and biologics.

What is the bfLEAP platform?

The bfLEAP platform is BullFrog AI's proprietary AI/ML-driven system that enables multi-dimensional data analysis to streamline drug discovery and reduce clinical trial failure rates.

How does BullFrog AI integrate AI into drug development?

The company integrates AI by using advanced analytics and causal AI methods to analyze complex biological data, identifying potential therapeutic targets and predictive biomarkers for various diseases.

What therapeutic areas does BullFrog AI focus on?

BullFrog AI is involved in researching treatments for liver diseases, obesity, psychiatric disorders, and oncology, among other complex medical conditions.

How does BullFrog AI differentiate itself in the biotechnology sector?

Its unique approach combines advanced AI analytics with strategic collaborations and a proprietary technology platform, enabling more efficient and precise drug discovery compared to traditional methods.

Who are BullFrog AI's key research collaborators?

The company collaborates with leading research institutions and clinical centers, which provide access to extensive biological datasets and expertise in genomic and molecular research.

What role does machine learning play in their operations?

Machine learning is central to analyzing vast amounts of clinical and biological data, facilitating the identification of new drug targets and optimizing the design and execution of clinical trials.

How does BullFrog AI improve clinical trial efficiency?

By leveraging its bfLEAP platform to extract actionable insights from clinical data, the company enhances patient selection, uncovers predictive biomarkers, and streamlines trial protocols, which can lead to more efficient clinical processes.
Stock BFRG logo
BULLFROG AI HLDGS INC

Nasdaq:BFRG

BFRG Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BFRG Stock Data

13.28M
6.87M
29.2%
11.72%
6.24%
Health Information Services
Pharmaceutical Preparations
Link
United States
GAITHERSBURG